DE3023396C2 - Arzneimittel zur intravenösen Krebstherapie - Google Patents
Arzneimittel zur intravenösen KrebstherapieInfo
- Publication number
- DE3023396C2 DE3023396C2 DE19803023396 DE3023396A DE3023396C2 DE 3023396 C2 DE3023396 C2 DE 3023396C2 DE 19803023396 DE19803023396 DE 19803023396 DE 3023396 A DE3023396 A DE 3023396A DE 3023396 C2 DE3023396 C2 DE 3023396C2
- Authority
- DE
- Germany
- Prior art keywords
- solution
- amino
- ascorbic acid
- boric acid
- cancer therapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000003814 drug Substances 0.000 title claims description 12
- 238000001990 intravenous administration Methods 0.000 title claims description 6
- 229940079593 drug Drugs 0.000 title claims description 4
- 238000011275 oncology therapy Methods 0.000 title claims description 3
- 239000000243 solution Substances 0.000 claims description 28
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 24
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 12
- 235000010323 ascorbic acid Nutrition 0.000 claims description 10
- 239000011668 ascorbic acid Substances 0.000 claims description 10
- 229960005070 ascorbic acid Drugs 0.000 claims description 10
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 9
- 239000004327 boric acid Substances 0.000 claims description 9
- 238000002347 injection Methods 0.000 claims description 8
- 239000007924 injection Substances 0.000 claims description 8
- 239000011780 sodium chloride Substances 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 5
- XMWRGALPOFHDFG-UHFFFAOYSA-N 1-(4-aminophenyl)-2-(diethylamino)-2-hydroxypropan-1-one Chemical compound CCN(CC)C(C)(O)C(=O)C1=CC=C(N)C=C1 XMWRGALPOFHDFG-UHFFFAOYSA-N 0.000 claims description 2
- WXYMJKAAOYJOBV-UHFFFAOYSA-N Cl.NC1=CC=C(C(=O)C(C(O)(N)CC)CC)C=C1 Chemical compound Cl.NC1=CC=C(C(=O)C(C(O)(N)CC)CC)C=C1 WXYMJKAAOYJOBV-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 description 12
- 238000011282 treatment Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- -1 borate ions Chemical class 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- MFBWAMMPCLWSSP-UHFFFAOYSA-N 3-amino-1-(4-aminophenyl)-2-ethyl-3-hydroxypentan-1-one Chemical compound NC1=CC=C(C(=O)C(C(O)(N)CC)CC)C=C1 MFBWAMMPCLWSSP-UHFFFAOYSA-N 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 229910052796 boron Inorganic materials 0.000 description 2
- 230000001461 cytolytic effect Effects 0.000 description 2
- 239000000824 cytostatic agent Substances 0.000 description 2
- 230000001085 cytostatic effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000005748 tumor development Effects 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940063013 borate ion Drugs 0.000 description 1
- 125000005619 boric acid group Chemical group 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000009200 cobalt therapy Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 229940085991 phosphate ion Drugs 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/22—Boron compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RO7997934A RO72294A2 (ro) | 1979-06-23 | 1979-06-23 | Produs medicamentos anticanceros si procedeu de preparare al acestuia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE3023396A1 DE3023396A1 (de) | 1981-01-22 |
| DE3023396C2 true DE3023396C2 (de) | 1983-02-17 |
Family
ID=20106169
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19803023396 Expired DE3023396C2 (de) | 1979-06-23 | 1980-06-23 | Arzneimittel zur intravenösen Krebstherapie |
Country Status (5)
| Country | Link |
|---|---|
| CA (1) | CA1142855A (enExample) |
| DE (1) | DE3023396C2 (enExample) |
| ES (1) | ES8104912A1 (enExample) |
| FR (1) | FR2459659A1 (enExample) |
| RO (1) | RO72294A2 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0875246A1 (en) * | 1997-04-04 | 1998-11-04 | Showa Denko Kabushiki Kaisha | Pharmaceutical preparation of ascorbic acid derivatives for medical treatment of cancer |
| RO116524B1 (ro) * | 1999-05-26 | 2001-03-30 | M. Corneliu Niculescu | Produs farmaceutic antineoplazic, uman şi veterinar, procedeu de obţinere şi metodă de tratament antineoplazic |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2684323A (en) * | 1950-10-21 | 1954-07-20 | Physiological Chemicals Compan | Procaine ascorbate preparation |
| FR3385M (fr) * | 1963-12-02 | 1965-06-21 | Sobio Lab | Compositions thérapeutiques a base d'ascorbate de procaine. |
-
1979
- 1979-06-23 RO RO7997934A patent/RO72294A2/ro unknown
-
1980
- 1980-06-16 ES ES492468A patent/ES8104912A1/es not_active Expired
- 1980-06-20 FR FR8013763A patent/FR2459659A1/fr active Granted
- 1980-06-20 CA CA000354516A patent/CA1142855A/en not_active Expired
- 1980-06-23 DE DE19803023396 patent/DE3023396C2/de not_active Expired
Non-Patent Citations (1)
| Title |
|---|
| NICHTS-ERMITTELT |
Also Published As
| Publication number | Publication date |
|---|---|
| ES492468A0 (es) | 1981-05-16 |
| ES8104912A1 (es) | 1981-05-16 |
| FR2459659A1 (fr) | 1981-01-16 |
| FR2459659B1 (enExample) | 1983-05-27 |
| DE3023396A1 (de) | 1981-01-22 |
| RO72294A2 (ro) | 1982-12-06 |
| CA1142855A (en) | 1983-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60103453T2 (de) | Verwendung von albuminstabilisiertem Paclitaxel zur Herstellung eines Arzneimittels zum Behandeln von festen Tumoren und das so erhaltene Arzneimittel | |
| DE3218761C2 (enExample) | ||
| DE69118859T2 (de) | Behandlung von Schlafstörungen unter Verwendung bestimmter Antidepressiva, z.B. Nefazodon | |
| DE69529213T2 (de) | Verwendung von magnesium enthaltenden verbindungen zur behandlung oder prophylaxe von krebs- und autoimmunkrankheiten | |
| DE68904922T2 (de) | Piroxicam in waessrigen loesungen enthaltende arzneizubereitungen und verfahren zu deren herstellung. | |
| DE1902227A1 (de) | Arzneimittel zur psychotherapeutischen Anwendung und Verfahren zu seiner Herstellung | |
| DE2417859A1 (de) | Verfahren zur herstellung von gemischten heparinsalzen | |
| DE3011437A1 (de) | Pharmazeutisches mittel zur heilung von entzuendlichen und/oder degenerativen und/oder atrophischen schleimhauterkrankungen | |
| DE3115080A1 (de) | Arzneimittel fuer die orale verabreichung und verfahren zu seiner herstellung | |
| DE3023396C2 (de) | Arzneimittel zur intravenösen Krebstherapie | |
| DE60101979T2 (de) | Lösung enthaltend N-[O-(p-pivaloyloxybenzenesulfonylamino)benzoyl]glyzin Mononatriumsalz Tetrahydrat und diese Lösung enthaltendes Arzneimittel | |
| DE69430427T2 (de) | Verwendung von ropivacaine zur herstellung eines analgetikums mit minimaler motorischer blockade | |
| DE19726871C1 (de) | Synergistisch wirkende Zusammensetzungen zur selektiven Bekämpfung von Tumorgewebe | |
| DE2427732A1 (de) | Mittel zum anaesthesieren von saeugetieren | |
| CH680494A5 (enExample) | ||
| DE3344086A1 (de) | Verwendung von azaspirogermanium-verbindungen zur behandlung von arthritis | |
| DE2444652A1 (de) | Mittel zur bekaempfung lokaler schmerzen | |
| DE69005874T2 (de) | Verwendung von Tetrachloroplatinatkomplexen mit Diazofarbstoffen als Antikrebsmittel. | |
| DE102007014375A1 (de) | Oleylphosphocholin | |
| DE69631597T2 (de) | Kombination aus einem beta rezeptorblocker und einem opioid | |
| DE960579C (de) | Verfahren zur Herstellung eines in der Hitze sterilisierbaren Adrenocorticotropin-Praeparates | |
| DE1617508C3 (de) | Antidepressive Mittel | |
| DE2011499A1 (de) | Arzneimittel aus Germaniumsäure und Cystein und Verfahren zu seiner Herstellung | |
| DE3802895A1 (de) | Kombinationspraeparat zur behandlung von nervenzell- und nervenfasererkrankungen und verletzungen | |
| DE2320858A1 (de) | Heilmittel fuer die behandlung von gestoertem blutkreislauf |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8110 | Request for examination paragraph 44 | ||
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition | ||
| 8328 | Change in the person/name/address of the agent |
Free format text: REINHARD, H., DIPL.-CHEM. DR.RER.NAT., PAT.-ANW., 8000 MUENCHEN |
|
| 8339 | Ceased/non-payment of the annual fee |